Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
29-30 March, 2025
Not Confirmed
Not Confirmed
31 March-01 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
29-30 March, 2025
Industry Trade Show
Not Confirmed
31 March-01 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
28 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/28/3051280/0/en/TREMFYA-guselkumab-receives-positive-CHMP-opinion-for-treatment-of-patients-with-moderately-to-severely-active-Crohn-s-Disease.html
03 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2025/02/03/3019238/0/en/CHMP-recommends-subcutaneous-RYBREVANT-amivantamab-for-the-treatment-of-patients-with-advanced-EGFR-mutated-non-small-cell-lung-cancer.html
23 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/23/3014089/0/en/Findings-from-pivotal-nipocalimab-Phase-3-study-in-a-broad-antibody-positive-population-of-people-living-with-generalised-myasthenia-gravis-published-in-The-Lancet-Neurology.html
21 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/21/3012357/0/en/European-Commission-approves-LAZCLUZE-lazertinib-in-combination-with-RYBREVANT-amivantamab-for-the-first-line-treatment-of-patients-with-EGFR-mutated-advanced-non-small-cell-lung-c.html
30 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/30/3002463/0/en/European-Commission-approves-RYBREVANT-amivantamab-in-combination-with-LAZCLUZE-lazertinib-for-the-first-line-treatment-of-patients-with-EGFR-mutated-advanced-non-small-cell-lung-c.html
10 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/10/2994233/0/en/CARVYKTI-ciltacabtagene-autoleucel-cilta-cel-demonstrated-significantly-higher-rates-of-minimal-residual-disease-negativity-compared-to-standard-therapies-in-the-CARTITUDE-4-study.html
ABOUT THIS PAGE
Janssen-Cilag is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN BORGO SAN MICHELE, ITALY bulk offered by Janssen-Cilag